<DOC>
	<DOCNO>NCT00081237</DOCNO>
	<brief_summary>RATIONALE : OSI-7904L may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy , oxaliplatin , work different way stop tumor cell divide stop grow die . Combining OSI-7904L oxaliplatin may kill tumor cell . PURPOSE : This phase I trial study side effect best dose OSI-7904L oxaliplatin treat patient refractory recurrent advance colorectal cancer .</brief_summary>
	<brief_title>OSI-7904L Oxaliplatin Treating Patients With Refractory Recurrent Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity OSI-7904L oxaliplatin patient refractory recurrent advance colorectal cancer . - Determine maximum tolerate dose regimen patient . - Determine safe dose regimen patient . Secondary - Determine pharmacokinetic profile regimen patient . - Determine safety profile regimen patient . - Determine antitumor activity regimen patient . OUTLINE : This nonrandomized , multicenter , open-label , dose-escalation study . Patients receive oxaliplatin IV 2 hour follow OSI-7904L IV 30 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos OSI-7904L oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . A maximum 12 patient receive treatment MTD . Patients follow every 8 week . PROJECTED ACCRUAL : A total 3-25 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Radiologic evidence advance disease At least 1 measurable lesion least 20 mm OR least 10 mm spiral CT scan Indicator lesion previously irradiate field allow provide irradiated lesion clearly progress OR new lesion develop irradiated field Failed 1 , 1 , line prior chemotherapy advanced/metastatic disease Disease progression chemotherapy OR within 6 month completion treatment No symptomatic brain metastasis meet follow criterion : Unstable Inadequately control fixeddose oral steroid Potentially lifethreatening Required radiotherapy past 28 day PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic AST ALT &lt; 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Bilirubin &lt; 1.5 time ULN No hepatitis No cirrhosis Renal Creatinine &lt; 1.5 time ULN Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month study participation HIV negative No preexist neuropathy â‰¥ grade 2 No active uncontrolled infection No serious illness medical condition No chronic alcohol abuse No know hypersensitivity systemic liposomal formulation compound chemically related OSI7904L oxaliplatin No prior psychiatric neurologic condition would preclude study compliance give informed consent PRIOR CONCURRENT THERAPY : Biologic therapy At least 21 day since prior immunotherapy At least 21 day since prior monoclonal antibody therapy Chemotherapy See Disease Characteristics At least 21 day since prior chemotherapy recovered* No prior oxaliplatin NOTE : *Alopecia allow Endocrine therapy See Disease Characteristics At least 21 day since prior hormonal therapy Radiotherapy See Disease Characteristics At least 21 day since prior radiotherapy recover No prior radiotherapy 25 % bone marrow reserve Surgery Recovered prior surgery Other At least 21 day since prior tyrosine kinase inhibitor therapy More 21 day since prior investigational agent No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>